Loading...
XSHE
300482
Market cap1.14bUSD
Jul 10, Last price  
16.84CNY
1D
2.06%
1Q
-6.24%
Jan 2017
-46.92%
IPO
211.01%
Name

Guangzhou Wondfo Biotech Co Ltd

Chart & Performance

D1W1MN
XSHE:300482 chart
P/E
P/S
3.78
EPS
Div Yield, %
2.42%
Shrs. gr., 5y
1.89%
Rev. gr., 5y
-5.78%
Revenues
2.09b
-31.91%
183,422,000227,353,601247,643,090365,395,892428,779,834547,353,2861,145,484,4821,650,059,4292,072,320,9012,810,841,2533,361,043,2765,680,513,1732,764,914,1563,064,809,3952,086,830,072
Net income
-63m
L
31,672,40037,908,55559,003,55398,364,053125,351,547144,986,731210,695,019307,744,494387,461,321634,170,286634,433,1491,197,063,465487,624,778561,628,536-63,024,899
CFO
463m
+28.01%
23,834,30074,836,212100,913,873104,470,301131,814,344112,007,117168,850,527247,609,248309,860,0701,061,837,071664,930,2901,682,171,310388,192,882361,711,130463,037,560
Dividend
May 20, 20250.4 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guangzhou Wondfo Biotech Co.,Ltd operates as a biotechnology enterprise, specializing in the research, development, production, and distribution of point-of-care testing (POCT) products. The company additionally provides rapid diagnostic tools and comprehensive solutions for managing chronic diseases. Its product catalog features an array of rapid test kits, addressing conditions like COVID-19, substance abuse, certain cancers, infectious diseases, fertility, and sexually transmitted infections. Furthermore, Wondfo Biotech offers immunofluorescence devices designed to identify cardiovascular conditions, inflammatory markers, kidney damage, hormonal imbalances (including sex hormones and thyroid function), diabetes, and specific tumor indicators. The firm also supplies analytical instruments, such as blood gas, optical coagulation, and dry chemistry analyzers. Established in 1992, the company's main operations are based in Guangzhou, China.
IPO date
Jun 30, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT